Vivesto AB · OMXSTO:VIVE
Vivesto AB — Oasmia Pharmaceutical — Q4 and FY ended April 30, 2020 Earnings Presentation
16 slides from Vivesto AB's earnings presentation, Jun 18, 2020
Slide 1: Oasmia Pharmaceutical AB Q4 and Year End Results Presentation
OASMIA PHARMACEUTICAL AB Q4 AND YEAR END RESULTS PRESENTATION FOR THE YEAR ENDED APRIL 30, 2020 F. R. Martelet, M.D. CEO 18 June 2020 NON-CONFIDENTIAL 1
Slide 2: Forward looking statement
Forward looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Today's speakers
Today’s speakers Francois Martelet, M.D. Michael af Winklerfelt Chief Executive Officer Chief Financial Officer NON-CONFIDENTIAL 3
Slide 4: Contents
Contents • Oasmia Overview • Q4 events and FY results • CEO outlook: Key Drivers • Executive summary NON-CONFIDENTIAL 4
Slide 5: Oasmia – an innovation-focused specialty pharmaceutical company
Oasmia – an innovation-focused specialty pharmaceutical company Founded in 1999 NASDAQ Stockholm 2010 HQ Uppsala, Sweden Market Cap approx. SEK 3,1 B 27 employees* XR17™ technology platform, allowing nano-sized particle R&D In-house Laboratory formulations of APIs, to be soluble in water – broad app
Slide 6: XR17 – multiple opportunities in oncology, human and animal health
XR17TM – multiple opportunities in oncology, human and animal health XR17™ ANIMAL ONCOLOGY OTHER HEALTH Therapeutic Areas Lung Cervical cancer cancer Prostate Breast Ovarian Bladder cancer cancer cancer cancer NON-CONFIDENTIAL 6
Slide 7: Building a diverse human health portfolio based on XR17 platform technology
Building a diverse human health portfolio based on XR17™ platform technology Registration / Product Indication Pre-clinical Phase I Phase II Phase III approval Geography Ovarian cancer Pre-NDA meeting USA Ovarian cancer EU / EEA1 Apealea® / Paclical® Ovarian cancer Russia (paclitaxel) Ovarian cancer
Slide 8: Oasmia Pharmaceutical AB Animal Health Portfolio
Oasmia Pharmaceutical AB Animal Health Portfolio Registration / Product Indication Pre-clinical Clinical approval Geography Paccal vet Mammary (paclitaxel) Carcinoma No US (Canines) Doxophos vet Lymphoma (doxorubicin) No US (Canines) Doxophos vet Paccal vet Potential next steps Potential Next steps
Slide 9: Apealea – offering improved treatment options
Apealea® – offering improved treatment options Approved in Current standard of care in Ovarian cancer is EU/EEA for carboplatin + paclitaxel treatment of first relapse ovarian Subset of patients cannot tolerate solvent-based cancer1 and in paclitaxel Russia for first line and relapsed Apealea® is an
Slide 10: Apealea – global partnership worth up to $698m + royalties
Apealea® – global partnership worth up to $698m + royalties Agreement with US-based Elevar Therapeutics, subsidiary of South Korea’s HLB Upfront payment $20M Double digit royalties on global Apealea® sales % Milestones based on regulatory and sales achievements $678M Oasmia retains sole control over
Slide 11: Q4 and Post-Period Overview
Q4 and Post-Period Overview • Global strategic partnership for the commercialization of Apealea® signed with Elevar in March 2020 ‒ Upfront payment of USD 20 million ‒ Milestone payments with a potential of up to USD 678 million and double digit royalties. • Apealea® 60 mg, launched in Sweden, Denma
Slide 12: Outcome of Strategic Review
Outcome of Strategic Review Goal: build Oasmia into a cash-flow positive speciality pharma company How this is achieved: Streamlining of our structure to become an agile and pro-active organisation Generating savings of 100 MSEK/year and achieving a monthly burn rate of < 10 MSEK Discontinuing comme
Slide 13: Q4 & FY 2020 Consolidated Income Statement in brief
Q4 & FY 2020 Consolidated Income Statement in brief 2019/20 2018/19 2019/20 2018/19 TSEK Feb-Apr Feb-Apr May-Apr May-Apr Net sales 201,265 266 201,843 1,980 Other operating income/loss 355 447 427 755 Change in inventories of products in progress and finished goods 13,137 -4,658 20,904 -5,148 Capita
Slide 14: Key ratios and other information
Key ratios and other information 2019/20 2018/19 2019/20 2018/19 Feb-Apr Feb-Apr May-Apr May-Apr 201,018 116,272 201,018 116,272 Cash and Cash equivalents * Number of shares at the end of the period, before and after 448,370 294,620 448,370 294,620 dilution, in thousands** Weighted average number of
Slide 15: Key value drivers
Key value drivers Short Term 12 months Mid Term 12-24 months • Docetaxel micellar clinical • Apealea Milestone payments & development plan Royalties • Phase 1 Study Initiation • Docetaxel micellar Phase 1 • Review of Animal Health Study Results Business assets • Realisation of cost control • XR-17 T
Slide 16: Strategic vision: Oasmia to become a significant speciality pharma Co.
Strategic vision: Oasmia to become a significant speciality pharma Co. Platform to build a Sweden-based cash-flow positive specialty pharma • Proven ability to register an oncology drug leader • Expand pipeline, including XR17™ technology • Strong cash position • Proven ability to negotiate substant
Oasmia Pharmaceutical — Q4 and FY ended April 30, 2020 Earnings Presentation on 6ix